392 related articles for article (PubMed ID: 19786842)
1. Plague vaccines and the molecular basis of immunity against Yersinia pestis.
Quenee LE; Schneewind O
Hum Vaccin; 2009 Dec; 5(12):817-23. PubMed ID: 19786842
[TBL] [Abstract][Full Text] [Related]
2. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
[TBL] [Abstract][Full Text] [Related]
3. Yersinia pestis caf1 variants and the limits of plague vaccine protection.
Quenee LE; Cornelius CA; Ciletti NA; Elli D; Schneewind O
Infect Immun; 2008 May; 76(5):2025-36. PubMed ID: 18347051
[TBL] [Abstract][Full Text] [Related]
4. Complete Protection Against
Zhang W; Song X; Zhai L; Guo J; Zheng X; Zhang L; Lv M; Hu L; Zhou D; Xiong X; Yang W
Front Immunol; 2022; 13():793382. PubMed ID: 35154110
[TBL] [Abstract][Full Text] [Related]
5. Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines.
Quenee LE; Ciletti NA; Elli D; Hermanas TM; Schneewind O
Vaccine; 2011 Sep; 29(38):6572-83. PubMed ID: 21763383
[TBL] [Abstract][Full Text] [Related]
6. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague.
Cornelius CA; Quenee LE; Overheim KA; Koster F; Brasel TL; Elli D; Ciletti NA; Schneewind O
Infect Immun; 2008 Dec; 76(12):5588-97. PubMed ID: 18794281
[TBL] [Abstract][Full Text] [Related]
7. Prospects for new plague vaccines.
Feodorova VA; Corbel MJ
Expert Rev Vaccines; 2009 Dec; 8(12):1721-38. PubMed ID: 19943765
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.
Miller NC; Quenee LE; Elli D; Ciletti NA; Schneewind O
Infect Immun; 2012 Apr; 80(4):1572-82. PubMed ID: 22252870
[TBL] [Abstract][Full Text] [Related]
9. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.
Lin JS; Park S; Adamovicz JJ; Hill J; Bliska JB; Cote CK; Perlin DS; Amemiya K; Smiley ST
Vaccine; 2010 Dec; 29(2):357-62. PubMed ID: 20840834
[TBL] [Abstract][Full Text] [Related]
10. A Recombinant Attenuated
Singh AK; Curtiss R; Sun W
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331960
[TBL] [Abstract][Full Text] [Related]
11. Novel CTL epitopes identified through a Y. pestis proteome-wide analysis in the search for vaccine candidates against plague.
Zvi A; Rotem S; Zauberman A; Elia U; Aftalion M; Bar-Haim E; Mamroud E; Cohen O
Vaccine; 2017 Oct; 35(44):5995-6006. PubMed ID: 28606812
[TBL] [Abstract][Full Text] [Related]
12. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H
Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.
Kilgore PB; Sha J; Hendrix EK; Motin VL; Chopra AK
mBio; 2021 Dec; 12(6):e0322321. PubMed ID: 34872353
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge.
Branger CG; Sun W; Torres-Escobar A; Perry R; Roland KL; Fetherston J; Curtiss R
Vaccine; 2010 Dec; 29(2):274-82. PubMed ID: 20979987
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.
DeBord KL; Anderson DM; Marketon MM; Overheim KA; DePaolo RW; Ciletti NA; Jabri B; Schneewind O
Infect Immun; 2006 Aug; 74(8):4910-4. PubMed ID: 16861680
[TBL] [Abstract][Full Text] [Related]
16. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.
Williamson ED; Packer PJ; Waters EL; Simpson AJ; Dyer D; Hartings J; Twenhafel N; Pitt ML
Vaccine; 2011 Jun; 29(29-30):4771-7. PubMed ID: 21570437
[TBL] [Abstract][Full Text] [Related]
17. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
[TBL] [Abstract][Full Text] [Related]
18. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J
Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.
Erova TE; Rosenzweig JA; Sha J; Suarez G; Sierra JC; Kirtley ML; van Lier CJ; Telepnev MV; Motin VL; Chopra AK
Clin Vaccine Immunol; 2013 Feb; 20(2):227-38. PubMed ID: 23239803
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW
Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
